Would you consider use of single-agent lenvatinib for advanced renal cell cancer after first-line therapy?

I have not used this combination because I feel more data is needed. Previous mTOR+VEGF combinations failed to improve outcomes when studied in large phase 3 trials, so I am a bit skeptical of these results and waiting for the phase 3 to ready out. In addition, there is significant toxicity wtih thi...

Monotherapy with lenvatinib is certainly active as seen in the phase 2 study so yes I think it is a reasonable choice. I agree TKI + I/O is active but would caution against doing this outside of a clinical trial.